CD24 and plasma cell myeloma: We constructed three types of bispecific BCMA-CD24-CAR T cells to target both the bulk tumor cells and drug-resistant myeloma cells and further improve the antitumor efficacy of CAR-T cells: one dual-targeted CAR-T cell (Bi-CAR-T) and two tandem CAR-T cells (Fig. 5a).